Picture loading failed.

Anti-EGFR therapeutic antibody (Pre-made Necitumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). It was counterproductive in non-squamous non-small-cell lung carcinoma.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-371-1mg 1mg 3090
GMP-Bios-ab-371-10mg 10mg 21890
GMP-Bios-ab-371-100mg 100mg 148000
GMP-Bios-ab-371-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EGFR therapeutic antibody (Pre-made Necitumumab biosimilar,Whole mAb)
INN Name Necitumumab
TargetEGFR
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesImClone Systems;Eli Lilly
Conditions ApprovedNon-small cell lung cancer
Conditions ActiveSolid tumours
Conditions DiscontinuedColorectal cancer
Development Techna